PA
MDXG icon

PharVision Advisers’s MiMedx Group MDXG Stock Holding History

PharVision Advisers’s Portfolio MDXG Stock Details MDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,955
Closed -$55.1K – 101
2026
Q1 		$55.1K Sell
13,955
-30,303
-68% -$153K 0.56% 83
2025
Q4 		$300K Buy
44,258
+26,986
+156% +$189K 0.15% 272
2025
Q3 		$121K Buy
+17,272
New +$120K 0.07% 602

Other funds holding MDXG

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $3.67B AUM 121.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

PharVision Advisers's MDXG Position: Q2 2026 in Review

PharVision Advisers sold out of MiMedx Group (MDXG) in Q2 2026, closing a stake of 13,955 shares — an estimated $55.1K sold.

PharVision Advisers first reported a position in MDXG in Q3 2025 and held it in 3 quarters. The position peaked at $300K in Q4 2025. 227 funds tracked by Wall St. Rank hold MDXG as of Q2 2026.

  • PharVision Advisers reported no remaining MiMedx Group position as of Q2 2026 after selling out during the quarter.
  • PharVision Advisers sold 13,955 MiMedx Group shares in Q2 2026, an estimated $55.1K.
  • PharVision Advisers first reported a position in MiMedx Group in Q3 2025 and held it in 3 quarters.
  • PharVision Advisers's MiMedx Group position peaked at $300K in Q4 2025.
  • 227 funds tracked by Wall St. Rank held MiMedx Group as of Q2 2026.

Based on PharVision Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.